holoxan pulver till injektions-/infusionsvätska, lösning
paranova läkemedel ab - ifosfamid - pulver till injektions-/infusionsvätska, lösning - ifosfamid 1 mg aktiv substans
cyclophosphamide accord 500 mg pulver till injektions-/infusionsvätska, lösning
accord healthcare b.v. - cyklofosfamidmonohydrat - pulver till injektions-/infusionsvätska, lösning - 500 mg - cyklofosfamidmonohydrat 534 mg aktiv substans; mannitol hjälpämne
cyclophosphamide accord 1000 mg pulver till injektions-/infusionsvätska, lösning
accord healthcare b.v. - cyklofosfamidmonohydrat - pulver till injektions-/infusionsvätska, lösning - 1000 mg - mannitol hjälpämne; cyklofosfamidmonohydrat 1069 mg aktiv substans
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
lunsumio
roche registration gmbh - mosunetuzumab - lymfom, follikel - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
tecvayli
janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiska medel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
talvey
janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiska medel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
idefirix
hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
aubagio
sanofi winthrop industrie - teriflunomide - multipel skleros - selektiva immunsuppressiva medel - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).